Persistence of cardiovascular risk after rofecoxib discontinuation

Archives of Internal Medicine

Volumn 170, Issue 22, 2010, Pages 2035-2036

  Ross, Joseph S ^a,b   Madigan, David ^c   Konstam, Marvin A ^d   Egilman, David S ^e   Krumholz, Harlan M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROFECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG FATALITY; DRUG MARKETING; DRUG USE; DRUG WITHDRAWAL; HUMAN; LETTER; LONG TERM CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT WITHDRAWAL;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LACTONES; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONES; TIME FACTORS;

EID: 78650135090     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.461     Document Type: Letter

References (5)

1. Bresalier RS, Sandler RS, Quan H, et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl JMed. 2005;352(11):1092-1102. (Pubitemid 40365350)
2. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372(9651):1756-1764.
3. Thal LJ, Ferris SH, Kirby L, et al; Rofecoxib Protocol 078 study group. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204-1215. (Pubitemid 40720980)
4. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for post-market pharmaceutical safety surveillance. Arch Intern Med. 2009;169(21):1976-1985.
5. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008;299(15):1813-1817. (Pubitemid 351549972)